Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Protective effectiveness of prior SARS-CoV-2 infection and hybrid immunity against Omicron infection and severe disease: a systematic review and meta-regression

View ORCID ProfileNiklas Bobrovitz, View ORCID ProfileHarriet Ware, View ORCID ProfileXiaomeng Ma, View ORCID ProfileZihan Li, View ORCID ProfileReza Hosseini, View ORCID ProfileChristian Cao, Anabel Selemon, View ORCID ProfileMairead Whelan, View ORCID ProfileZahra Premji, View ORCID ProfileHanane Issa, Brianna Cheng, View ORCID ProfileLaith J. Abu Raddad, View ORCID ProfileDavid Buckeridge, View ORCID ProfileMaria Van Kerkhove, View ORCID ProfileVanessa Piechotta, View ORCID ProfileMelissa Higdon, View ORCID ProfileAnnelies Wilder-Smith, View ORCID ProfileIsabel Bergeri, View ORCID ProfileDaniel Feikin, View ORCID ProfileRahul K. Arora, View ORCID ProfileMinal Patel, View ORCID ProfileLorenzo Subissi
doi: https://doi.org/10.1101/2022.10.02.22280610
Niklas Bobrovitz
1Temerty Faculty of Medicine, University of Toronto, Toronto, Canada
2Department of Critical Care Medicine, University of Calgary, Canada
3Centre for Health Informatics, Cumming School of Medicine, University of Calgary, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Niklas Bobrovitz
  • For correspondence: niklas.bobrovitz{at}mail.utoronto.ca subissil{at}who.int
Harriet Ware
3Centre for Health Informatics, Cumming School of Medicine, University of Calgary, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Harriet Ware
Xiaomeng Ma
4Institute of Health Policy Management and Evaluation, University of Toronto, Toronto, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Xiaomeng Ma
Zihan Li
3Centre for Health Informatics, Cumming School of Medicine, University of Calgary, Canada
5Department of Bioengineering, University of California, Berkeley, United States of America
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Zihan Li
Reza Hosseini
3Centre for Health Informatics, Cumming School of Medicine, University of Calgary, Canada
6School of Population and Public Health, University of British Columbia, Vancouver, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Reza Hosseini
Christian Cao
1Temerty Faculty of Medicine, University of Toronto, Toronto, Canada
3Centre for Health Informatics, Cumming School of Medicine, University of Calgary, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Christian Cao
Anabel Selemon
3Centre for Health Informatics, Cumming School of Medicine, University of Calgary, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mairead Whelan
3Centre for Health Informatics, Cumming School of Medicine, University of Calgary, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Mairead Whelan
Zahra Premji
7Libraries, University of Victoria, Victoria, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Zahra Premji
Hanane Issa
8Institute of Health Informatics, University College London, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Hanane Issa
Brianna Cheng
1Temerty Faculty of Medicine, University of Toronto, Toronto, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Laith J. Abu Raddad
9Infectious Disease Epidemiology Group, Weill Cornell Medicine–Qatar, Cornell University, Doha, Qatar
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Laith J. Abu Raddad
David Buckeridge
10Department of Epidemiology and Biostatistics, School of Population and Global Health, McGill University, Montreal, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for David Buckeridge
Maria Van Kerkhove
11Health Emergencies Programme, World Health Organization, Geneva, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Maria Van Kerkhove
Vanessa Piechotta
12Department of Infectious Disease Epidemiology, Robert Koch Institute, Berlin, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Vanessa Piechotta
Melissa Higdon
13International Vaccine Access Center, Department of International Health, John Hopkins Bloomberg School of Public Health, Baltimore, United States of America
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Melissa Higdon
Annelies Wilder-Smith
14Department of Immunizations, Vaccines and Biologicals, World Health Organization, Geneva, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Annelies Wilder-Smith
Isabel Bergeri
11Health Emergencies Programme, World Health Organization, Geneva, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Isabel Bergeri
Daniel Feikin
14Department of Immunizations, Vaccines and Biologicals, World Health Organization, Geneva, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Daniel Feikin
Rahul K. Arora
3Centre for Health Informatics, Cumming School of Medicine, University of Calgary, Canada
15Institute of Biomedical Engineering, University of Oxford, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Rahul K. Arora
Minal Patel
14Department of Immunizations, Vaccines and Biologicals, World Health Organization, Geneva, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Minal Patel
Lorenzo Subissi
11Health Emergencies Programme, World Health Organization, Geneva, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Lorenzo Subissi
  • For correspondence: niklas.bobrovitz{at}mail.utoronto.ca subissil{at}who.int
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Summary

Background We aimed to systematically review the magnitude and duration of the protective effectiveness of prior infection (PE) and hybrid immunity (HE) against Omicron infection and severe disease.

Methods We searched pre-print and peer-reviewed electronic databases for controlled studies from January 1, 2020, to June 1, 2022. Risk of bias (RoB) was assessed using the Risk of Bias In Non-Randomized Studies of Interventions (ROBINS-I)-Tool. We used random-effects meta-regression to estimate the magnitude of protection at 1-month intervals and the average change in protection since the last vaccine dose or infection from 3 months to 6 or 12 months. We compared our estimates of PE and HE to previously published estimates of the magnitude and durability of vaccine effectiveness (VE) against Omicron.

Findings Eleven studies of prior infection and 15 studies of hybrid immunity were included. For prior infection, there were 97 estimates (27 at moderate RoB and 70 at serious RoB), with the longest follow up at 15 months. PE against hospitalization or severe disease was 82·5% [71·8-89·7%] at 3 months, and 74·6% [63·1-83·5%] at 12 months. PE against reinfection was 65·2% [52·9-75·9%] at 3 months, and 24·7% [16·4-35·5%] at 12 months. For HE, there were 153 estimates (78 at moderate RoB and 75 at serious RoB), with the longest follow up at 11 months for primary series vaccination and 4 months for first booster vaccination. Against hospitalization or severe disease, HE involving either primary series vaccination or first booster vaccination was consistently >95% for the available follow up. Against reinfection, HE involving primary series vaccination was 69·0% [58·9-77·5%] at 3 months after the most recent infection or vaccination, and 41·8% [31·5-52·8%] at 12 months, while HE involving first booster vaccination was 68·6% [58·8-76·9%] at 3 months, and 46·5% [36·0-57·3%] at 6 months. Against hospitalization or severe disease at 6 months, hybrid immunity with first booster vaccination (effectiveness 95·3% [81·9-98·9%]) or with primary series alone (96·5% [90·2-98·8%]) provided significantly greater protection than prior infection alone (80·1% [70·3-87·2%]), first booster vaccination alone (76·7% [72·5-80·4%]), or primary series alone (64·6% [54·5-73·6%]). Results for protection against reinfection were similar.

Interpretation Prior infection and hybrid immunity both provided greater and more sustained protection against Omicron than vaccination alone. All protection estimates waned quickly against infection but remained high for hospitalisation or severe disease. Individuals with hybrid immunity had the highest magnitude and durability of protection against all outcomes, reinforcing the global imperative for vaccination.

Funding WHO COVID-19 Solidarity Response Fund and the Coalition for Epidemic Preparedness Innovations.

Evidence before this study The global emergence and rapid spread of Omicron (B.1.1.529) variant of concern, characterized by their ability to escape immunity, has required scientists and policymakers to reassess the population protection against Omicron infection and severe disease. So far, few systematic reviews have incorporated data on Omicron, and none have examined the protection against Omicron conferred by hybrid immunity (i.e. the immunity gained from the combination of vaccination and prior infection) which is now widespread globally. While one preprint has recently reported protection from prior infection over time, no systematic review has systematically compared the magnitude and duration of vaccination, prior infection, and hybrid immunity. A large single-country study has reported that protection from either infection or hybrid immunity against Omicron infection wanes to low levels at 15 months, but is relatively stable against severe disease.

Added value of this study Prior infection and hybrid immunity both provided greater and more sustained protection against Omicron than vaccination alone. Individuals with hybrid immunity had the highest magnitude and durability of protection against all outcomes; protection against severe disease remained above 95% until the end of available follow-up at 11 months after hybrid immunity with primary series and 4 months after hybrid immunity with booster vaccination, and was sustained at these high levels of protection in projections to 12 months and 6 months, respectively.

Implications of all the available evidence These results may serve to tailor guidance on the optimal number and timing of vaccinations. At the public health level, these findings can be combined with data on local infection prevalence, vaccination rates, and their timing. In settings with high seroprevalence, limited resources, and competing health priorities, it may be reasonable to focus on achieving high coverage rates with primary series among individuals who are at higher risk of poor outcome, as this will provide a high level of protection against severe disease for at least one year among those with prior infection. Furthermore, given the waning protection for both infection-and vaccine induced immunity against infection or reinfection, mass vaccination could be timed for roll-out prior to periods of expected increased incidence, such as the winter season. At the individual level, these results can be combined with knowledge of a person’s infection and vaccination history. A six-month delay in booster may be justified after the last infection or vaccination for individuals with a known prior infection and full primary series vaccination. Further follow-up of the protective effectiveness of hybrid immunity against hospitalization or severe disease for all vaccines is needed to clarify how much waning of protection might occur with longer duration since the last infection or vaccination. Producing estimates of protection for new variant-containing vaccines will be crucial for COVID-19 vaccine policy and decision-making bodies. Policy makers considering the use and timing of vaccinations should include the local extent of past infection, the protection conferred by prior infection or hybrid immunity, and the duration of this protection as key considerations to inform their decision-making.

Competing Interest Statement

The authors have declared no competing interest.

Clinical Protocols

https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=318605

Funding Statement

This work was supported by World Health Organization (WHO) through funding from the WHO Solidarity Response Fund and the Coalition for Epidemic Preparedness Innovations (CEPI). The funders had no role in the collection, analysis, and interpretation of data; in the writing of the report, or in the decision to submit the paper for publication. The views reported do not necessarily reflect the official position of WHO or CEPI.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Updated funding statement and citations.

Data Availability

Data extracted from published articles and used in our analysis will be made available upon request after approval of a study proposal. Data provided to us directly by authors of the included studies will not be shared unless permission from the original study authors is provided. Obtaining these permissions will be the responsibility of the investigators making the request for data.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted October 24, 2022.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Protective effectiveness of prior SARS-CoV-2 infection and hybrid immunity against Omicron infection and severe disease: a systematic review and meta-regression
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Protective effectiveness of prior SARS-CoV-2 infection and hybrid immunity against Omicron infection and severe disease: a systematic review and meta-regression
Niklas Bobrovitz, Harriet Ware, Xiaomeng Ma, Zihan Li, Reza Hosseini, Christian Cao, Anabel Selemon, Mairead Whelan, Zahra Premji, Hanane Issa, Brianna Cheng, Laith J. Abu Raddad, David Buckeridge, Maria Van Kerkhove, Vanessa Piechotta, Melissa Higdon, Annelies Wilder-Smith, Isabel Bergeri, Daniel Feikin, Rahul K. Arora, Minal Patel, Lorenzo Subissi
medRxiv 2022.10.02.22280610; doi: https://doi.org/10.1101/2022.10.02.22280610
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Protective effectiveness of prior SARS-CoV-2 infection and hybrid immunity against Omicron infection and severe disease: a systematic review and meta-regression
Niklas Bobrovitz, Harriet Ware, Xiaomeng Ma, Zihan Li, Reza Hosseini, Christian Cao, Anabel Selemon, Mairead Whelan, Zahra Premji, Hanane Issa, Brianna Cheng, Laith J. Abu Raddad, David Buckeridge, Maria Van Kerkhove, Vanessa Piechotta, Melissa Higdon, Annelies Wilder-Smith, Isabel Bergeri, Daniel Feikin, Rahul K. Arora, Minal Patel, Lorenzo Subissi
medRxiv 2022.10.02.22280610; doi: https://doi.org/10.1101/2022.10.02.22280610

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (434)
  • Allergy and Immunology (760)
  • Anesthesia (222)
  • Cardiovascular Medicine (3316)
  • Dentistry and Oral Medicine (366)
  • Dermatology (282)
  • Emergency Medicine (480)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1175)
  • Epidemiology (13403)
  • Forensic Medicine (19)
  • Gastroenterology (900)
  • Genetic and Genomic Medicine (5182)
  • Geriatric Medicine (483)
  • Health Economics (786)
  • Health Informatics (3286)
  • Health Policy (1146)
  • Health Systems and Quality Improvement (1199)
  • Hematology (432)
  • HIV/AIDS (1024)
  • Infectious Diseases (except HIV/AIDS) (14657)
  • Intensive Care and Critical Care Medicine (917)
  • Medical Education (478)
  • Medical Ethics (128)
  • Nephrology (526)
  • Neurology (4957)
  • Nursing (263)
  • Nutrition (735)
  • Obstetrics and Gynecology (889)
  • Occupational and Environmental Health (797)
  • Oncology (2531)
  • Ophthalmology (730)
  • Orthopedics (284)
  • Otolaryngology (348)
  • Pain Medicine (323)
  • Palliative Medicine (90)
  • Pathology (547)
  • Pediatrics (1308)
  • Pharmacology and Therapeutics (552)
  • Primary Care Research (559)
  • Psychiatry and Clinical Psychology (4225)
  • Public and Global Health (7526)
  • Radiology and Imaging (1717)
  • Rehabilitation Medicine and Physical Therapy (1022)
  • Respiratory Medicine (982)
  • Rheumatology (480)
  • Sexual and Reproductive Health (500)
  • Sports Medicine (425)
  • Surgery (551)
  • Toxicology (73)
  • Transplantation (237)
  • Urology (206)